$VTEX

Gomes Andre Spolidoro Ferreira sold $13K of VTEX (indirect holdings)

Gomes Andre Spolidoro Ferreira (Chief Strategy Officer) sold 3,000 indirectly-held shares of VTEX (VTEX) at $4.19 on 2026-10-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Gomes Andre Spolidoro Ferreira
Published Oct 20, 2026, 1:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 20, 2026, 1:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$VTEX
Neutral
high confidence
Mentioned
$VTEX
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VTEXNeutralLow
01

Why it matters

Provides a factual update on insider holdings but limited market impact.

02

Market read

Minor insider sell with negligible effect on VTEX stock price.

03

What to watch

Potential tax planning or portfolio rebalancing could be driving the sale.

Relevance 2/10Novelty 2/10Timing: today

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$VTEXNeutralHigh confidence
Context

Chief Strategy Officer sold 3,000 shares for $12,570 via a 10b5-1 plan, reducing holdings to 27,400 shares.

Expected impact

likely slight pressure as the market prices the insider sale.

Evidence & confidence

The sale is small relative to market cap and disclosed via Form 4, providing limited new information.

Market effects

None significant for e‑commerce sector.

No broader regional effect.

Limited to VTEX investors.

Counterpoint

The sale may be routine and not indicative of future performance.

Key entities

  • Gomes Andre Spolidoro Ferreira

    Chief Strategy Officer of VTEX.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$VTEXMed

VTEX (VTEX) Just Turned A Profit Corner, But Growth Is Slowing

VTEX (NYSE:VTEX) reported Q2 2026 results showing improved profitability with non-GAAP income from operations up 62.4% YoY to $13.8M, and free cash flow up 79.1% to $12.7M. However, revenue growth slowed to 1.3% YoY on an FX-neutral basis, with management expecting flat growth for Q3. The company repurchased 6.2M shares for $23.2M during the quarter.

$VTEXMedAI 8/10

VTEX (VTEX) Q2 2026 Earnings Call Transcript

VTEX reported Q2 2026 results in an earnings call. GMV was $5.7B, up 7% FX-neutral. Subscription revenue was $63.8M, up 1.3% FX-neutral. Non-GAAP operating income rose 62% to $13.8M, with a 21.4% margin. Free cash flow was $12.7M, up 79%. Q3 guidance calls for flat FX-neutral subscription growth.

$VTEXMedAI 8/10

VTEX Q2 Earnings Call Highlights

VTEX (NYSE:VTEX) reported Q2 margin and cash flow improvement and guided for Q3 and full-year low-single-digit FX-neutral subscription revenue growth and low-20% non-GAAP operating and free cash flow margins. Q2 non-GAAP subscription gross margin rose to 81.8%. Free cash flow rose 79% to $12.7M. VTEX repurchased 6.2M shares at $3.76.

$VTEXMed

VTEX (VTEX): Financial results for Q2 2026

VTEX (VTEX) furnished an SEC Form 6-K — earnings release. VTEX Reports Second Quarter 2026 Financial Results Subscription revenue grew 11.4% (+1.3% FXN), with GMV up 17.8% (+7.0% FXN) Non-GAAP income from operations increased 62.4% to US$13.8 million, reaching a 21.4% margin Free cash flow increased 79.1% to US$12.7 million, reaching a